


Amendments to the Claims


This list of claims replaces the prior version of the claims in the application:

Claims 1-49 (Canceled)

5

Claim 50 (Currently amended): A method to treat or ameliorate an inflammation condition in a subject, comprising administering to the subject an effective amount of a compound having the structure





wherein, the dotted lines are optional double bonds;

R¹ is -OH, -SH, an ester, an ether, a thioester or a thioether;

5 R² is -H, -OH, -SH, an ester, an ether, a thioester or a thioether;

R³ is -OH, =O, an ester, an ether, a thioester or a thioether;

R⁴ is -OH, -SH, =S, an ester, an ether, a thioester or a thioether;

R⁵ is -CH₃ or -CH₂OH;

R⁶ is -H or -CH₃;

10 R⁷ is -CH₂- or -CHR¹⁰-;

R⁸ is -CH₂-, -O- or -NH-;

R⁹ is -CH₂-, -CHR¹⁰- or -CHR¹⁰-CHR¹⁰-; and

each R¹⁰ independently is -OH, an ester, an ether, -SH, a thioester, a thioether or a halogen.

15

Claims 51-53 (Canceled)

Claim 54 (Previously presented): The method of claim 50 wherein R¹ and R³ are -OH; R² is -H; R⁴ is -OH or -SH.

20

Claim 55 (Previously presented): The method of claim 50 wherein R¹, R³ and R⁴ are -OH and R² is -H.

5 Claim 56 (Withdrawn): The method of claim 50 wherein R¹, R², R³ and R⁴ are -OH.

10 Claim 57 (Previously presented): The method of claim 50 wherein the inflammation condition is atopic asthma, allergic respiratory disease, allergic rhinitis, atopic dermatitis, subepithelial fibrosis in airway hyperresponsiveness, chronic sinusitis, perennial allergic rhinitis, allergic bronchopulmonary aspergillosis in cystic fibrosis patients, Crohn's disease, ulcerative colitis, inflammatory bowel disease or fibrosing alveolitis.






15 Claim 58 (Previously presented): The method of claim 57 wherein R¹ and R³ are -OH, R² is -H and R⁴ is -OH or -SH.


Claim 59 (Previously presented): The method of claim 57 wherein R¹, R³ and R⁴ are -OH and R² is -H.

20 Claim 60 (Withdrawn): The method of claim 57 wherein R¹, R², R³ and R⁴ are -OH.

25 Claim 61 (Previously presented): The method of claim 57 wherein the inflammation condition is atopic asthma.

Claim 62 (Currently amended): The method of claim 61 wherein the compound has the structure





Claim 63 (Previously presented): The method of claim 62 wherein R^1 and R^3 are -OH, R^2 is -H, and R^4 is -OH or -SH;

5

Claim 64 (Previously presented): The method of claim 62 wherein R^1 , R^3 and R^4 are -OH and R^2 is -H.

Claim 65 (Withdrawn): The method of claim 62 wherein R^1 , R^2 , R^3 and R^4 are -OH.

10


Claim 66 (Currently amended): The method of claim 62 wherein the compound is $3\beta,7\beta,16\alpha,17\beta$ -tetrahydroxyandrost-5-ene, $3\alpha,7\beta,16\alpha,17\beta$ -tetrahydroxyandrost-5-ene, $3\beta,7\beta,16\beta,17\beta$ -tetrahydroxyandrost-5-ene, $3\beta,7\alpha,16\alpha,17\beta$ -tetrahydroxyandrost-5-ene, $3\beta,7\alpha,16\alpha,17\alpha$ -tetrahydroxyandrost-5-ene, $3\beta,7\beta,16\alpha,17\beta$ -tetrahydroxyandrost-1,5-diene, $3\alpha,7\beta,16\alpha,17\beta$ -tetrahydroxyandrost-1,5-diene, $3\beta,7\beta,16\beta,17\beta$ -tetrahydroxyandrost-1,5-diene, $3\beta,7\alpha,16\alpha,17\beta$ -tetrahydroxyandrost-5-ene, $3\beta,7\alpha,16\alpha,17\alpha$ -tetrahydroxyandrost-5-ene, ~~$3\beta,16\alpha,17\beta$ -trihydroxy-5 α -androstane~~, $3\alpha,16\alpha,17\alpha$ -trihydroxy-5 α -androstane, $3\alpha,16\beta,17\beta$ -trihydroxy-5 α -androstane, ~~[[or]]~~ $3\beta,16\beta,17\beta$ -trihydroxy-5 α -androstane, $3\alpha,16\alpha,17\beta$ -trihydroxy-5 α -androstane, $3\alpha,17\beta$ -dihydroxy-5 α -androstane-16-one or $3\beta,16\alpha,17\beta$ -trihydroxy-5 β -androstane.


15

20

Claim 67 (Previously presented): The method of claim 66 wherein the compound is 3 α ,16 β ,17 β -trihydroxy-5 α -androstane or 3 β ,16 β ,17 β -trihydroxy-5 α -androstane.

5 Claim 68 (Withdrawn-currently amended): A formulation comprising one or
more excipients and at least one **[[a]]** compound having the structure





wherein, the dotted lines are optional double bonds;

R¹ is -OH, -SH, an ester, an ether, a thioester or a thioether;

R² is -H, -OH, -SH, an ester, an ether, a thioester or a thioether;

5 R³ is -OH, =O, an ester, an ether, a thioester or a thioether;

R⁴ is -OH, -SH, =S, an ester, an ether, a thioester or a thioether;

R⁵ is -CH₃ or -CH₂OH;

R⁶ is -H, or -CH₃;


R⁷ is -CH₂- or -CHR¹⁰-;

10 R⁸ is -CH₂-, -O- or -NH-;


R⁹ is -CH₂-, -CHR¹⁰-, -O- or -NH-; and

each R¹⁰ independently is -OH, an ester, an ether, -SH, a thioester, a thioether or a halogen.


15 Claim 69 (Withdrawn): The formulation of claim 68 wherein the compound has the structure




20 Claim 70 (Withdrawn): The formulation of claim 68 wherein the compound has the structure



Claim 71 (Withdrawn): The formulation of claim 68 wherein the compound has the structure



Claim 72 (Withdrawn): The formulation of claim 68 wherein the compound has the structure



Claim 73 (Withdrawn-currently amended): The formulation of claim 68 wherein the compound is 3 β ,7 β ,16 α ,17 β -tetrahydroxyandrost-5-ene, 3 α ,7 β ,16 α ,17 β -tetrahydroxyandrost-5-ene, 3 β ,7 β ,16 β ,17 β -tetrahydroxyandrost-5-ene, 3 β ,7 α ,16 α ,17 β -tetrahydroxyandrost-5-ene, 3 β ,7 α ,16 α ,17 α -tetrahydroxyandrost-5-ene, 3 β ,7 β ,16 α ,17 β -tetrahydroxyandrost-1,5-diene, 3 α ,7 β ,16 α ,17 β -tetrahydroxyandrost-1,5-diene, 3 β ,7 β ,16 β ,17 β -tetrahydroxyandrost-1,5-diene, 3 β ,7 α ,16 α ,17 β -tetrahydroxyandrost-5-ene, 3 β ,7 α ,16 α ,17 α -tetrahydroxyandrost-5-ene, 3 β ,16 α ,17 β -trihydroxy-5 α -androstane, 3 α ,16 α ,17 α -trihydroxy-5 α -androstane, 3 α ,16 β ,17 β -trihydroxy-5 α -


androstane, or ~~3 β ,16 β ,17 β -trihydroxy-5 α -androstane~~, 3 α ,16 α ,17 β -trihydroxy-5 α -androstane, 3 α ,17 β -trihydroxy-5 α -androstane-16-one or 3 β -16 α -17 β -trihydroxy-5 β -androstane.

5 Claim 74 (Withdrawn): The formulation of claim 68 wherein the formulation is a liquid for parenteral administration.

10 Claim 75 (Withdrawn): The formulation of claim 68 wherein the liquid is a non-aqueous solution containing less than about 0.3% v/v water or a suspension in an aqueous liquid.

Claim 76 (Withdrawn): The formulation of claim 68 wherein the formulation is a solid suitable for oral, buccal, sublingual or aerosol administration.

15 Claim 77 (Currently amended): The method of claim 57 wherein the inflammation condition is atopic asthma and the compound has the structure



Claim 78 (previously presented): The method of claim 77 wherein R¹ is -OH, -SH, an ester or an ether and R⁴ is -OH, -SH, an ester or an ether.

Claim 79 (Previously presented): The method of claim 78 wherein R^2 is -H, -OH, -SH, an ester or an ether and R^3 is -OH, -SH, an ester or an ether.

5 Claim 80 (Previously presented): The method of claim 79 wherein R^1 is -OH or -SH, R^2 is -H, and R^3 is -OH.


Claim 81 (Previously presented): The method of claim 80 wherein R^1 and R^4 are -OH.

10 Claim 82 (Previously presented): The method of claim 81 wherein R^7 , R^8 and R^9 are -CH₂-.

Claim 83 (Previously presented): The method of claim 80 wherein R^6 is -CH₃.

15

Claim 84 (Previously presented): The method of claim 83 wherein the compound has the structure



20